Integrated Filing-Governance



General information about company

Scrip Code 543904
NSE Symbol MANKIND
MSEI Symbol NOTLISTED
ISIN INE634S01028
Name of the entity MANKIND PHARMA LIMITED
Date of start of financial year 01-Apr-2024
Date of end of financial year 31-Mar-2025
Reporting Quarter Yearly
Date of Quarter Ending 31-Mar-2025
Type of company Equity
Whether Annexure I (Part A) of the SEBI Circular dated December 31, 2024 related to Compliance Report on Corporate Governance is applicable to the entity? Yes
Whether Annexure I (Part B) of the SEBI Circular dated December 31, 2024 related to Investor Grievance Redressal Report is Applicable to the entity? Yes
Whether Annexure I (Part C) of the SEBI Circular dated December 31, 2024 related to Disclosure of Acquisition of Shares or Voting Rights in Unlisted Companies is Applicable to the entity? No
Reason For Part C Of Annexure I Disclosure Of Acquisition Of Shares OrVotingRightsInUnlistedCompaniesIsNotApplicableToTheEntity Pursuant to proviso of sub-para 1(c) of Para A of Part A of Schedule III of SEBI LODR Regulations, 2015, no disclosure is required to be made in this report for the quarter ended on March 31, 2025.
Whether Annexure I (Part D) of the SEBI Circular dated December 31, 2024 related to Disclosure of Imposition of Fine or Penalty is Applicable to the entity? Yes
Whether Annexure I (Part E) of the SEBI Circular dated December 31, 2024 related to Disclosure of Updates to Ongoing Tax Litigations or Disputes is Applicable to the entity? Yes
Whether Annexure I (Part F) of the SEBI Circular dated December 31, 2024 related to Disclosure Of Loans / Guarantees / Comfort Letters / Securities Etc. is Applicable to the entity? Yes
Risk management committee Yes
Market Capitalisation as per immediate previous Financial Year Top 500 listed entities
Is SCORE ID Available ? Yes
SCORE Registration ID COMM00995
Reason For No SCORE ID
Type of Submission Original
Remarks (website dissemination)



Annexure I
Annexure I to be submitted by listed entity on quarterly basis
I. Composition of Board of Directors
Disclosure of notes on composition of board of directors explanatory The directorship and committee membership details of Mr. Surendra Lunia are as on 18-02-2025. Updated details post his cessation from directorship are not available.
Whether the listed entity has a Regular Chairperson Yes
Whether Chairperson is related to MD or CEO Yes Disqualification of Directors under section 164 of the Companies Act, 2013
Sr Title (Mr / Ms) Name of the Director PAN DIN Category 1 of directors Category 2 of directors Category 3 of directors Date of Birth Whether the director is disqualified? Start Date of disqualification End Date of disqualification Details of disqualification Current status Whether special resolution passed? [Refer Reg. 17(1A) of Listing Regulations] Date of passing special resolution Initial Date of appointment Date of Re-appointment Date of cessation Tenure of director (in months) No of Directorship in listed entities including this listed entity (Refer Regulation 17A of Listing Regulations) No of Independent Directorship in listed entities including this listed entity [with reference to proviso to regulation 17A(1) & 17A(2)] Number of memberships in Audit/ Stakeholder Committee(s) including this listed entity (Refer Regulation 26(1) of Listing Regulations) No of post of Chairperson in Audit/ Stakeholder Committee held in listed entities including this listed entity (Refer Regulation 26(1) of Listing Regulations) Reason for Cessation Notes for not providing PAN Notes for not providing DIN
1 Mr. Ramesh Juneja 00283399 Executive Director Chairperson related to Promoter 07-Jul-1955 No Active NA 03-Jul-1991 15-May-2024 1 0 0 0
2 Mr. Rajeev Juneja 00283481 Executive Director Not Applicable MD 28-Jul-1965 No Active NA 22-Dec-1992 15-May-2024 1 0 0 0
3 Mr. Sheetal Arora 00704292 Executive Director Not Applicable CEO 18-Nov-1975 No Active NA 21-Sep-2007 15-May-2024 1 0 2 0
4 Mr. Satish Kumar Sharma 07615602 Executive Director Not Applicable 03-Jun-1973 No Active NA 23-Sep-2016 23-Sep-2021 1 0 0 0
5 Mr. Tilokchand Punamchand Ostwal 00821268 Non-Executive - Independent Director Not Applicable 07-Nov-1954 No Active NA 01-Jan-2020 01-Jan-2023 63 2 2 3 2
6 Mr. Bharat Anand 02806475 Non-Executive - Independent Director Not Applicable 13-Jul-1976 No Active NA 31-Aug-2018 31-Aug-2021 79.01 4 4 3 0
7 Mrs. Vijaya Sampath 00641110 Non-Executive - Independent Director Not Applicable 26-May-1953 No Active NA 01-Aug-2022 01-Aug-2022 32 7 7 8 1
8 Mr. Vivek Kalra 00426240 Non-Executive - Independent Director Not Applicable 14-Feb-1964 No Active NA 01-Aug-2022 01-Aug-2022 32 1 1 2 0
9 Mr. Surendra Lunia 00121156 Non-Executive - Independent Director Not Applicable 18-Oct-1962 No Active NA 19-Feb-2015 19-Feb-2020 18-Feb-2025 120 1 1 2 1



Annexure 1

II. Composition of Committees
Disclosure of notes on composition of committees explanatory



Audit Committee Details
Whether the Audit Committee has a Regular Chairperson Yes
Sr DIN Number Name of Committee members Category 1 of directors Category 2 of directors Date of Appointment Date of Cessation Remarks
1 00641110 Vijaya Sampath Non-Executive - Independent Director Chairperson 18-Feb-2025
2 00704292 Sheetal Arora Executive Director Member 02-Aug-2023
3 00821268 Tilokchand Punamchand Ostwal Non-Executive - Independent Director Member 14-Feb-2020
4 02806475 Bharat Anand Non-Executive - Independent Director Member 31-Aug-2018
5 00426240 Vivek Kalra Non-Executive - Independent Director Member 02-Aug-2023
6 00121156 Surendra Lunia Non-Executive - Independent Director Chairperson 19-Feb-2015 18-Feb-2025



Nomination and remuneration committee
Whether the Nomination and remuneration committee has a Regular Chairperson Yes
Sr DIN Number Name of Committee members Category 1 of directors Category 2 of directors Date of Appointment Date of Cessation Remarks
1 00821268 Tilokchand Punamchand Ostwal Non-Executive - Independent Director Chairperson 14-Feb-2020
2 02806475 Bharat Anand Non-Executive - Independent Director Member 31-Aug-2018
3 00641110 Vijaya Sampath Non-Executive - Independent Director Member 02-Aug-2023
4 00121156 Surendra Lunia Non-Executive - Independent Director Chairperson 19-Feb-2015 18-Feb-2025



Stakeholders Relationship Committee
Whether the Stakeholders Relationship Committee has a Regular Chairperson Yes
Sr DIN Number Name of Committee members Category 1 of directors Category 2 of directors Date of Appointment Date of Cessation Remarks
1 00821268 Tilokchand Punamchand Ostwal Non-Executive - Independent Director Chairperson 01-Aug-2022
2 00704292 Sheetal Arora Executive Director Member 01-Aug-2022
3 00426240 Vivek Kalra Non-Executive - Independent Director Member 02-Aug-2023
4 00121156 Surendra Lunia Non-Executive - Independent Director Member 01-Aug-2022 18-Feb-2025



Risk Management Committee
Whether the Risk Management Committee has a Regular Chairperson Yes
Sr DIN Number Name of Committee members Category 1 of directors Category 2 of directors Date of Appointment Date of Cessation Remarks
1 00704292 Sheetal Arora ED Chairperson 01-Aug-2022
2 00641110 Vijaya Sampath ID Member 02-Aug-2023
3 02806475 Bharat Anand ID Member 02-Aug-2023
4 02046864 Ashutosh Dhawan Global Chief Financial Officer Member 01-Aug-2022



Annexure 1
III. Meeting of Board of Directors
Disclosure of notes on meeting of board of directors explanatory
Sr Date(s) of meeting (Enter dates of Previous quarter and Current quarter in chronological order) Maximum gap between any two consecutive (in number of days) Notes for not providing Date Whether requirement of Quorum met (Yes/No) Total Number of Directors as on date of the meeting Number of Directors present* (All directors including Independent Director) No. of Independent Directors attending the meeting*
1 05-Nov-2024 Yes 9 8 4
2 03-Dec-2024 27 Yes 9 8 5
3 16-Dec-2024 12 Yes 9 9 5
4 08-Jan-2025 22 Yes 9 8 4
5 23-Jan-2025 14 Yes 9 9 5



Annexure 1
IV. Meeting of Committees
Disclosure of notes on meeting of committees explanatory
Sr Name of Committee Date(s) of meeting (Enter dates of Previous quarter and Current quarter in chronological order) Maximum gap between any two consecutive (in number of days) Name of other committee Reson for not providing date Whether requirement of Quorum met (Yes/No) Total Number of Directors in the Committee as on date of the meeting Number of Directors Present (All Directors including Independent Director) No. of Independent Directors attending the meeting* No. of members attending the meeting (other than Board of Directors)
1 Audit Committee 05-Nov-2024 Yes 5 4 3 0
2 Audit Committee 03-Dec-2024 27 Yes 5 5 4 0
3 Audit Committee 16-Dec-2024 12 Yes 5 5 4 0
4 Audit Committee 23-Jan-2025 37 Yes 5 5 4 0
5 Nomination and remuneration committee 05-Nov-2024 Yes 4 3 3 0
6 Nomination and remuneration committee 03-Dec-2024 27 Yes 4 4 4 0
7 Nomination and remuneration committee 08-Jan-2025 35 Yes 4 3 3 0
8 Nomination and remuneration committee 23-Jan-2025 14 Yes 4 4 4 0



Annexure 1
VI. Affirmations
Sr Subject Compliance status (Yes/No)
1 The composition of Board of Directors is in terms of SEBI (Listing obligations and disclosure requirements) Regulations, 2015 Yes
2 The composition of the following committees is in terms of SEBI(Listing obligations and disclosure requirements) Regulations, 2015 a. Audit Committee Yes
3 The composition of the following committees is in terms of SEBI(Listing obligations and disclosure requirements) Regulations, 2015. b. Nomination & remuneration committee Yes
4 The composition of the following committees is in terms of SEBI(Listing obligations and disclosure requirements) Regulations, 2015. c. Stakeholders relationship committee Yes
5 The composition of the following committees is in terms of SEBI(Listing obligations and disclosure requirements) Regulations, 2015. d. Risk management committee (applicable to the top 1000 listed entities) Yes
6 The committee members have been made aware of their powers, role and responsibilities as specified in SEBI (Listing obligations and disclosure requirements) Regulations, 2015. Yes
7 The meetings of the board of directors and the above committees have been conducted in the manner as specified in SEBI (Listing obligations and disclosure requirements) Regulations, 2015 Yes
8 This report and/or the report submitted in the previous quarter has been placed before Board of Directors. Yes
9 Any comments/observations/advice of Board of Directors may be mentioned here: This Intergarted Governance Report for the quarter ended on March 31, 2025 will be placed before the Board in the upcoming Board meeting.



Annexure 1
Sr Subject Compliance status
1 Name of signatory Hitesh Kumar Jain
2 Designation Company Secretary and Compliance Officer



Details of Cyber security incidence
Whether as per Regulation 27(2)(ba) of SEBI (LODR) Regulations, 2015 there has been cyber security incidents or breaches or loss of data or documents during the quarter No
Other details of cyber security incidence or breaches or loss of data event
Number of cyber security incidence or breaches or loss of data event occurred during the quarter
Sr Date of the event Brief details of the event



Annexure II to be submitted by listed entity at the end of the financial year (for the whole of financial year)
I. Disclosure on website in terms of LODR Regulation
Sr Item Compliance status (Yes/No/NA) If status is No details of non-compliance may be given here. Web address
1.1 Details of business Yes https://www.mankindpharma.com/company
1.2 Memorandum of Association and Articles of Association Yes https://www.mankindpharma.com/wp-content/uploads/2025/01/MOA-AOA-Mankind-Pharma.pdf
1.3 Brief profile of board of directors including directorship and full time positions in body corporates Yes https://www.mankindpharma.com/investors-relations/mankind-glance/
2 Terms and conditions of appointment of independent directors Yes https://www.mankindpharma.com/wp-content/uploads/2024/12/appointment-of-independent-directors.pdf
3 Composition of various committees of board of directors Yes https://www.mankindpharma.com/investors-relations/mankind-glance/
4 Code of conduct of board of directors and senior management personnel Yes https://www.mankindpharma.com/wp-content/uploads/2024/12/code-of-conduct.pdf
5 Details of establishment of vigil mechanism or whistle blower policy Yes https://www.mankindpharma.com/wp-content/uploads/2024/12/details-of-establishment.pdf
6 Criteria of making payments to non-executive directors Yes https://www.mankindpharma.com/investors-relations/disclosure-under-regulation-46-of-sebi-lodr
7 Policy on dealing with related party transactions Yes https://www.mankindpharma.com/wp-content/uploads/2025/01/Policy-on-dealing-with-related-party-transactions_23012025.pdf
8 Policy for determining material subsidiaries Yes https://www.mankindpharma.com/wp-content/uploads/2024/12/policy-for-determing-material.pdf
9 Details of familiarization programmes imparted to independent directors Yes https://www.mankindpharma.com/wp-content/uploads/2024/12/details-of-familiarization.pdf
10 Contact information of the designated officials of the listed entity who are responsible for assisting and handling investor grievances Yes https://www.mankindpharma.com/investors-relations/company-contact
11 Email address for grievance redressal and other relevant details Yes https://www.mankindpharma.com/investors-relations/company-contact
12 Financial results Yes https://www.mankindpharma.com/investors-relations/financials
13 Shareholding pattern Yes https://www.mankindpharma.com/investors-relations/shareholder-information
14 Details of agreements entered into with the media companies and/or their associates Yes https://www.mankindpharma.com/investors-relations/disclosure-under-regulation-46-of-sebi-lodr
15.1 Schedule of analyst or institutional investor meet and presentation prepared by listed entity for analyst or institutional investor meet Yes https://www.mankindpharma.com/investors-relations/financials
15.2 Audio or video recordings and transcripts of post earnings/quarterly calls Yes https://www.mankindpharma.com/investors-relations/financials
16 New name and the old name of the listed entity NA
17 Advertisements as per regulation 47 (1) Yes https://www.mankindpharma.com/investors-relations/financials/
18 Credit rating or revision in credit rating obtained Yes https://www.mankindpharma.com/investors-relations/financials
19 Separate audited financial statements of each subsidiary of the listed entity Yes https://www.mankindpharma.com/investors-relations/annual-report
20 Secretarial compliance report Yes https://www.mankindpharma.com/investors-relations/intimation-to-stock-exchange/
21 Materiality policy as per regulation 30 (4) Yes https://www.mankindpharma.com/wp-content/uploads/2025/04/Determination-of-materiality-of-events-and-information.pdf
22 Disclosure of contact details of KMP who are authorized for the purpose of determining materiality as required under regulation 30(5) Yes https://www.mankindpharma.com/wp-content/uploads/2025/01/Outcome08012025.pdf
23 Disclosures under regulation 30(8) Yes https://www.mankindpharma.com/investors-relations/intimation-to-stock-exchange
24 Statements of deviation(s) or variations(s) as specified in regulation 32 Yes https://www.mankindpharma.com/wp-content/uploads/2025/01/Finaloutcome_sd.pdf
25 Dividend distribution policy as specified in regulation 43A (1) Yes https://www.mankindpharma.com/wp-content/uploads/2024/12/dividend-distribution-policy-1684998215.pdf
26.1 Annual return as provided under section 92 of the Companies Act 2013 Yes https://www.mankindpharma.com/investors-relations/annual-report/
26.2 Employee benefit scheme documents framed in terms of SEBI (SBEB) regulations 2021
27 Confirmation that the above disclosures are in a separate section as specified in regulation 46(2) Yes https://www.mankindpharma.com/investors-relations/disclosure-under-regulation-46-of-sebi-lodr
28 Compliance with regulation 46(3) with respect to accuracy of disclosures on the website and timely updation Yes https://www.mankindpharma.com/investors-relations/disclosure-under-regulation-46-of-sebi-lodr
29 Disclosure of notes on website in terms of Listing Regulations explanatory


Annexure II
II. Annual Affirmations
Sr Particulars Regulation Number Compliance status (Yes/No/NA) If status is No details of non-compliance may be given here.
1 Independent director(s) have been appointed in terms of specified criteria of independence and/or eligibility 16(1)(b) Yes
2 Board Composition 17(1), 17(1A) & 17(1C), 17(1D) & 17(1E) Yes
3 Meeting Of Board Of Directors 17(2) Yes
4 Quorum of board meeting 17(2A) Yes
5 Review of Compliance Reports 17(3) Yes
6 Plans for orderly succession for appointments 17(4) Yes
7 Code of Conduct 17(5) Yes
8 Fees/compensation 17(6) Yes
9 Minimum Information 17(7) Yes
10 Compliance Certificate 17(8) Yes
11 Risk Assessment & Management 17(9) Yes
12 Performance Evaluation of Independent Directors 17(10) Yes
13 Recommendation of Board 17(11) Yes
14 Maximum number of Directorships 17A Yes
15 Composition of Audit Committee 18(1) Yes
16 Meeting of Audit Committee 18(2) Yes
17 Role of Audit Committee and information to be reviewed by the audit committee 18(3) Yes
18 Composition of nomination & remuneration committee 19(1) & (2) Yes
19 Quorum of Nomination and Remuneration Committee meeting 19(2A) Yes
20 Meeting of Nomination and Remuneration Committee 19(3A) Yes
21 Role of Nomination and Remuneration Committee 19(4) Yes
22 Composition of Stakeholder Relationship Committee 20(1), 20(2) & 20(2A) Yes
23 Meeting of Stakeholders Relationship Committee 20(3A) Yes
24 Role of Stakeholders Relationship Committee 20(4) Yes
25 Composition and role of risk management committee 21(1),(2),(3),(4) Yes
26 Meeting of Risk Management Committee 21(3A) Yes
27 Quorum of Risk Management Committee meeting 21(3B) Yes
28 Gap between the meetings of the Risk Management Committee 21(3C) Yes
29 Vigil Mechanism 22 Yes
30 Policy for related party Transaction 23(1), (1A), (5), (6), & (8) Yes
31 Prior or Omnibus approval of Audit Committee for all related party transactions 23(2), (3) Yes
32 Approval for material related party transactions 23(4) NA
33 Disclosure of related party transactions on consolidated basis 23(9) Yes
34 Composition of Board of Directors of unlisted material Subsidiary 24(1) Yes
35 Other Corporate Governance requirements with respect to subsidiary of listed entity 24(2),(3),(4),(5) & (6) Yes
36 Alternate Director to Independent Director 25(1) NA
37 Maximum Tenure 25(2) Yes
38 Appointment, Re-appointment or removal of an Independent Director through special resolution or the alternate mechanism 25(2A) NA
39 Meeting of independent directors 25(3) & (4) Yes
40 Familiarization of independent directors 25(7) Yes
41 Declaration from Independent Director 25(8) & (9) Yes
42 Directors and Officers insurance 25(10) Yes
43 Confirmation with respect to appointment of Independent Directors who resigned from the listed entity 25(11) Yes
44 Memberships in Committees 26(1) Yes
45 Affirmation with compliance to code of conduct from members of Board of Directors and Senior management personnel 26(3) Yes
46 Policy with respect to Obligations of directors and senior management 26(2) & 26(5) Yes
47 Approval of the Board and shareholders for compensation or profit sharing in connection with dealings in the securities of the listed entity 26(6) NA
48 Vacancies in respect Key Managerial Personnel 26A(1) & 26A(2), 26A(3) Yes
Any other information to be provided - Add Notes



Annexure II
III. Affirmations
Sr Particulars Compliance status (Yes/No/NA)
1 The Listed Entity has approved Material Subsidiary Policy and the Corporate Governance requirements with respect to subsidiary of Listed Entity have been complied Yes
Any other information to be provided



Annexure II
1 Name of signatory Hitesh Kumar Jain
2 Designation Company Secretary and Compliance Officer



Additional Half yearly Disclosure
Any Other Information for Disclosure of Loans / Guarantees / Comfort Letters / Securities Etc.
I. Disclosure of Loans/ guarantees/comfort letters /securities etc.refer note below
(A)Any loan or any other form of debt advanced by the listed entity directly or indirectly to
Entity Aggregate amount advanced during six months Balance outstanding at the end of six months
Promoter or any other entity controlled by them 0 0
Promoter Group or any other entity controlled by them 0 0
Directors (including relatives) or any other entity controlled by them 0 0
KMPs or any other entity controlled by them 0 0
(B) Any guarantee / comfort letter (by whatever name called) provided by the listed entity directly or indirectly, in connection with any loan(s) or any other form of debt availed By
Entity Type (guarantee, comfort letter etc.) Aggregate amount of issuance during six months Balance outstanding at the end of six months(taking into account any invocation)
Promoter or any other entity controlled by them 0 0 0
Promoter Group or any other entity controlled by them 0 0 0
Directors (including relatives) or any other entity controlled by them 0 0 0
KMPs or any other entity controlled by them 0 0 0
(C) Any security provided by the listed entity directly or indirectly, in connection with any loan(s) or any other form of debt availed by
Entity Type of security (cash, shares etc.) Aggregate value of security provided during six months Balance outstanding at the end of six months
Promoter or any other entity controlled by them 0 0 0
Promoter Group or any other entity controlled by them 0 0 0
Directors (including relatives) or any other entity controlled by them 0 0 0
KMPs or any other entity controlled by them 0 0 0
(D) Additional Information
II. Affirmations
Affirmations Compliance Status Company Remarks
All loans (or other form of debt), guarantees, comfort letters (by whatever name called) or securities in connection with any loan(s) (or other form of debt) given directly or indirectly by the listed entity to promoter(s), promoter group, director(s) (including their relatives), key managerial personnel (including their relatives) or any entity controlled by them are in the economic interest of the company. Yes
Name Ashutosh Dhawan
Designation Chief Financial Officer
Place New Delhi
Date 29-Apr-2025



Signatory Details
Name of signatory Hitesh Kumar Jain
Designation of person Company Secretary and Compliance Officer
Place New Delhi
Date 29-Apr-2025


Investor Grievance Details
No. of investor complaints pending at the beginning of Quarter 0
No. of investor complaints received during the Quarter 1
No. of investor complaints disposed off during the Quarter 1
No. of investor complaints those remaining unresolved at the end of the Quarter 0


Disclosure of Acquisition of Shares or Voting Rights in Unlisted Companies-
The details of acquisition of shares or voting rights in unlisted companies during the quarter in terms of sub-para 1 of para A of Part A of Schedule III are given below
Any Other Information for Disclosure of Acquisition of Shares or Voting Rights in Unlisted Companies
Sr. No. Name of the unlisted company in which shares or voting rights have been acquired Date of acquisition Aggregate holding (% shares or voting rights) as at the end of the previous quarter % shares or voting rights acquired during the quarter Aggregate holding (% shares or voting rights) as at the end of the quarter


Disclosure of Imposition of Fine or Penalty
The details of imposition of fine or penalty during the quarter in terms of sub-para 20 of para A of Part A of Schedule III are given below:
Any Other Information for Disclosure of Imposition of Fine or Penalty
Sr. No. Name of the authority Nature and details of the action(s) taken or order(s) passed Date of receipt of direction or order, including any ad interim or interim orders, or any other communication from the authority Details of the violation(s)/ contravention(s) committed or alleged to be committed Impact on financial, operation or other activities of the listed entity, quantifiable in monetary terms to the extent possible
1 Office of the Superintendent, GST & Central Excise, Cuttack Order-in-Original dated 25 January 2025 passed u/s 74 of Central Goods and Services Tax Act, 2017 for FY 2017-18 levying penalty of Rs. 39,508/- The order pertains to Lifestar Pharma Private Limited, which has been merged with Mankind Pharma Limited since March 2023. The Tax and interest demand in this matter is below the material threshold limit currently applicable to the Company. 28-Jan-2025 The order has been passed on the contention that there is an alleged mismatch in figures reported in GSTR-1 vs GSTR-3B for FY 2017-18 Based on the assessment of facts and prevailing law, the Company is of the view that the demand including penalty levied is arbitrary and unjustified. The Company does not agree with the order and will take appropriate action(s) for the same including filing of an appeal if required. There is no material impact on the company's financials, operations, or other activities.
2 Office of Sales Tax Officer Class II / AVATO. Delhi Order-in-Original dated 27 February 2025 passed u/s 73 of Central Goods and Services Tax Act, 2017 for FY 2020-21 levying penalty of INR 104,806/- 27-Feb-2025 The order has been passed on the contention that the Company has short paid the tax as per GSTR-9 Based on the assessment of facts and prevailing law, the Company is of the view that the demand including penalty levied is arbitrary and unjustified. The Company does not agree with the order and will take appropriate action(s) for the same including filing of an appeal if required. There is no material impact on the company's financials, operations, or other activities.
3 Office of State Taxes Officer, Jammu and Kashmir The order pertains to Magnet Labs Private Limited, which has been merged with Mankind Pharma Limited since March 2023. Order-in-Original dated 22 February 2025 passed u/s 73 of Central Goods and Services Tax Act, 2017 for FY 2020-21 levying penalty of INR 40,000/- 22-Feb-2025 The GST Authority has passed the Order on account of disallowance of alleged inadmissible ITC. Based on the assessment of facts and prevailing law, the Company is of the view that the demand including penalty levied is arbitrary and unjustified. The Company does not agree with the order and will take appropriate action(s) for the same including filing of an appeal if required. There is no material impact on the company's financials,operations, or other activities.
4 Office of Assistant Commissioner, Chennai, Tamil Nadu Order-in-Original dated 17 February 2025 passed u/s 73 of Central Goods and Services Tax Act, 2017 for FY 2020-21 levying penalty of INR 20,000/- 17-Feb-2025 The GST Authority has passed the order on account of non payment of interest on delayed payment of tax Based on the assessment of facts and prevailing law, the Company is of the view that the demand including penalty levied is arbitrary and unjustified. The Company does not agree with the order and will take appropriate action(s) for the same including filing of an appeal if required. There is no material impact on the company's financials, operations, or other activities.


Disclosure of Updates to Ongoing Tax Litigations or Disputes
The updates on tax litigations or disputes in terms of sub-para 8 of para B of Part A of Schedule III read with corresponding provisions of Annexure 18 of the Master Circular are given below:

Any Other Information for Disclosure of Updates to Ongoing Tax Litigations or Disputes
Sr. No. Name of the opposing party Date of initiation of the litigation / dispute Status of the litigation / dispute as per last disclosure Current status of the litigation / dispute
1 DCIT, Central Circle - 29, New Delhi 25-Feb-2025 The IT Authority vide assessment order has raised additional tax demand (including interest) of INR 111.68 crores under section 143(3) read with Section 144C(3) of the Income-tax Act, 1961 (‘the Act’) on account of adjustment made u/s 80IC/80IE of the Act and disallowance of various expenditures u/s 37(1) of the Act. Against the order, the company has preferred appeal before Ld. CIT(A) on 28-03-2025, which is yet to be disposed off.
2 DCIT, Central Circle - 29, New Delhi 25-Mar-2025 The IT Authority vide assessment order has raised additional tax demand (including interest) of INR 183.11 crores under Section 147 read with Section 143(3) of the Income-tax Act, 1961 (‘the Act’) on account of disallowance of various expenditures u/s 37(1) of the Act. Against the order, the company has preferred appeal before Ld. CIT(A) on 31-03-2025, which is yet to be disposed off.
3 Superintendent, GST & Central Excise, Cuttack 25-Jan-2025 Order-in-Original dated 25 January 2025 passed u/s 74 of Central Goods and Services Tax Act, 2017 for FY 2017-18 levying penalty of Rs. 39,508/- Since amount involved under dispute was very small, the Company have paid the same and matter is closed as on date
4 Sales Tax Officer Class II / AVATO Delhi 27-Feb-2025 Order-in-Original dated 27 February 2025 passed u/s 73 of Central Goods and Services Tax Act, 2017 for FY 2020-21 levying penalty of INR 104,806/-. Based on the assessment of facts and prevailing law, the Company is of the view that the demand including penalty levied is arbitrary and unjustified. The Company does not agree with the order and is in process of filing of appeal against the same.
5 State Taxes Officer, Jammu and Kashmir 22-Feb-2025 Order-in-Original dated 22 February 2025 passed u/s 73 of Central Goods and Services Tax Act, 2017 for FY 2020-21 levying penalty of INR 40,000/- Based on the assessment of facts and prevailing law, the Company is of the view that the demand including penalty levied is arbitrary and unjustified. The Company has filed an appeal to the appropriate appellate forum against the said order
6 Assistant Commissioner, Chennai, Tamil Nadu 17-Feb-2025 Order-in-Original dated 17 February 2025 passed u/s 73 of Central Goods and Services Tax Act, 2017 for FY 2020-21 levying penalty of INR 20,000/- Since amount involved under dispute was very small, the Company have paid the same and matter is closed as on date
7 Additional Commissioner, Central Tax, CGST& CX Kolkata 26-Dec-2024 Order-in-Original passed u/s 74 of Central Goods and Services Tax Act, 2017 covering FY 2017-18 to FY2021-22 levying penalty of INR 2,27,83,935/-. Based on the assessment of facts and prevailing law, the Company is of the view that the demand including penalty levied is arbitrary and unjustified. The Company has filed an appeal to the appropriate appellate forum against the said order
8 Deputy Commissioner of State tax, Trimurti Nagar, Nagpur 28-Feb-2025 Order-in-Original passed u/s 73 of Central Goods and Services Tax Act, 2017 for FY 2021-22 levying penalty of INR 46,32,582/-. Based on the assessment of facts and prevailing law, the Company is of the view that the demand including penalty levied is arbitrary and unjustified. The Company does not agree with the order and is in process of filing of appeal against the same.